Supernus Pharmaceuticals Inc
Company Profile
Business description
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Contact
9715 Key West Avenue
RockvilleMD20850
USAT: +1 301 838-2500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
778
Stocks News & Analysis
stocks
Eli Lilly receives FDA approval to add another oral GLP-1 to market
stocks
Our top ASX picks in every sector
stocks
Which of the 3 giant AI IPOs should you buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.90 | 124.80 | -1.40% |
| CAC 40 | 7,908.82 | 72.45 | -0.91% |
| DAX 40 | 22,916.77 | 382.12 | -1.64% |
| Dow JONES (US) | 46,196.17 | 369.57 | -0.79% |
| FTSE 100 | 10,393.58 | 28.79 | 0.28% |
| HKSE | 25,116.53 | 177.50 | -0.70% |
| NASDAQ | 21,612.97 | 227.98 | -1.04% |
| Nikkei 225 | 52,463.27 | 1,276.41 | -2.38% |
| NZX 50 Index | 12,902.15 | 76.28 | 0.59% |
| S&P 500 | 6,527.28 | 48.04 | -0.73% |
| S&P/ASX 200 | 8,579.50 | 105.50 | -1.21% |
| SSE Composite Index | 3,919.29 | 29.27 | -0.74% |